Northfield Suffers Setback On Phase III PolyHeme Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Data discrepancies, protocol violations mar preliminary top-line results for experimental blood substitute.
You may also be interested in...
Northfield Labs Reports Verified Data From Troubled Phase III PolyHeme Study
“Exceeding the noninferiority endpoint by a small margin” in the study should not keep the product out of the broad emergency trauma setting, CEO Gould tells “The Pink Sheet” DAILY.
Northfield Labs Reports Verified Data From Troubled Phase III PolyHeme Study
“Exceeding the noninferiority endpoint by a small margin” in the study should not keep the product out of the broad emergency trauma setting, CEO Gould tells “The Pink Sheet” DAILY.
U.S. Navy Plans To Proceed With Hemopure Development
Following negative review by FDA advisory committee, Navy will work on a revised clinical trial protocol for a scaled-down Phase II study.